368 related articles for article (PubMed ID: 23884071)
1. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.
Aspinall EJ; Corson S; Doyle JS; Grebely J; Hutchinson SJ; Dore GJ; Goldberg DJ; Hellard ME
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S80-9. PubMed ID: 23884071
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
Graf C; Mücke MM; Dultz G; Peiffer KH; Kubesch A; Ingiliz P; Zeuzem S; Herrmann E; Vermehren J
Clin Infect Dis; 2020 May; 70(11):2355-2365. PubMed ID: 31513710
[TBL] [Abstract][Full Text] [Related]
3. Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs.
Latham NH; Doyle JS; Palmer AY; Vanhommerig JW; Agius P; Goutzamanis S; Li Z; Pedrana A; Gottfredsson M; Bouscaillou J; Luhmann N; Mazhnaya A; Altice FL; Saeed S; Klein M; Falade-Nwulia OO; Aspinall E; Hutchinson S; Hellard ME; Sacks-Davis R
Liver Int; 2019 Dec; 39(12):2244-2260. PubMed ID: 31125496
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
Muller A; Vlahov D; Akiyama MJ; Kurth A
Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs.
Weir A; McLeod A; Innes H; Valerio H; Aspinall EJ; Goldberg DJ; Barclay ST; Dillon JF; Fox R; Fraser A; Hayes PC; Kennedy N; Mills PR; Stanley AJ; Aitken C; Gunson R; Templeton K; Hunt A; McIntyre P; Hutchinson SJ
Drug Alcohol Depend; 2016 Aug; 165():53-60. PubMed ID: 27268294
[TBL] [Abstract][Full Text] [Related]
9. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
[TBL] [Abstract][Full Text] [Related]
10. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
Martin NK; Foster GR; Vilar J; Ryder S; Cramp ME; Gordon F; Dillon JF; Craine N; Busse H; Clements A; Hutchinson SJ; Ustianowski A; Ramsay M; Goldberg DJ; Irving W; Hope V; De Angelis D; Lyons M; Vickerman P; Hickman M
J Viral Hepat; 2015 Apr; 22(4):399-408. PubMed ID: 25288193
[TBL] [Abstract][Full Text] [Related]
11. Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection.
Valerio H; Goldberg DJ; Lewsey J; Weir A; Allen S; Aspinall EJ; Barclay ST; Bramley P; Dillon JF; Fox R; Fraser A; Hayes PC; Innes H; Kennedy N; Mills PR; Stanley AJ; Hutchinson SJ
Drug Alcohol Depend; 2015 Sep; 154():125-31. PubMed ID: 26183402
[TBL] [Abstract][Full Text] [Related]
12. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
13. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis.
Artenie A; Stone J; Fraser H; Stewart D; Arum C; Lim AG; McNaughton AL; Trickey A; Ward Z; Abramovitz D; Alary M; Astemborski J; Bruneau J; Clipman SJ; Coffin CS; Croxford S; DeBeck K; Emanuel E; Hayashi K; Hermez JG; Low-Beer D; Luhmann N; Macphail G; Maher L; Palmateer NE; Patel EU; Sacks-Davis R; Van Den Boom W; van Santen DK; Walker JG; Hickman M; Vickerman P;
Lancet Gastroenterol Hepatol; 2023 Jun; 8(6):533-552. PubMed ID: 36996853
[TBL] [Abstract][Full Text] [Related]
14. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial.
Hilsden RJ; Macphail G; Grebely J; Conway B; Lee SS
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S90-6. PubMed ID: 23884072
[TBL] [Abstract][Full Text] [Related]
15. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ;
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S129-37. PubMed ID: 23884061
[TBL] [Abstract][Full Text] [Related]
17. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.
Arain A; Robaeys G
World J Gastroenterol; 2014 Sep; 20(36):12722-33. PubMed ID: 25278674
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus reinfection following treatment among people who use drugs.
Grady BP; Schinkel J; Thomas XV; Dalgard O
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S105-10. PubMed ID: 23884057
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study.
Litwin AH; Jost J; Wagner K; Heo M; Karasz A; Feinberg J; Kim AY; Lum PJ; Mehta SH; Taylor LE; Tsui JI; Pericot-Valverde I; Page K;
Contemp Clin Trials; 2019 Dec; 87():105859. PubMed ID: 31669450
[TBL] [Abstract][Full Text] [Related]
20. Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis.
Munari SC; Traeger MW; Menon V; Latham NH; Manoharan L; Luhmann N; Baggaley R; MacDonald V; Verster A; Siegfried N; Conway B; Klein M; Bruneau J; Stoové MA; Hellard ME; Doyle JS
Liver Int; 2023 Dec; 43(12):2625-2644. PubMed ID: 37817387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]